Æterna Zentarisの%ショート株式
Æterna Zentarisの%ショート株式は何ですか。
Æterna Zentaris, Inc.の%ショート株式は0.15%です。
%ショート株式の定義は何ですか。
浮動小数点の割合は、浮動小数点と比較して短絡している株式の割合をパーセンテージで表したものです。
Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.
TSXのセクタHealth Careにおける%ショート株式の企業と比べるÆterna Zentaris
Æterna Zentarisは何をしますか。
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Æterna Zentarisと類似の%ショート株式
- Nuveen Floating Rate Income Opportunity Fundの%ショート株式は0.14%です。
- China Customer Relations Centers Incの%ショート株式は0.14%です。
- Alj Regional Incの%ショート株式は0.14%です。
- Wayside Technology Incの%ショート株式は0.14%です。
- LifeSci Acquisition IIの%ショート株式は0.14%です。
- Liberty All-Star Equity Fundの%ショート株式は0.14%です。
- Æterna Zentarisの%ショート株式は0.15%です。
- Superior Industries Internationalの%ショート株式は0.16%です。
- Freshiiの%ショート株式は0.16%です。
- Melroseの%ショート株式は0.16%です。
- Manhattan Bridge Capital Incの%ショート株式は0.16%です。
- Visionaryの%ショート株式は0.16%です。
- DiaMedica Therapeuticsの%ショート株式は0.16%です。